Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
SSRI Impact On Sperm Quality: A Randomized Placebo Controlled Trial
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 11, 2022
Pharmacokinetic Evaluation of Serum Testosterone Concentrations After Administration of Clomiphene Citrate
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 11, 2022
Tissue Collection for Drug Screening and Bioanalysis
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 14, 2022
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy with PRA023 in Subjects with Moderately to Severely Active Ulcerative Colitis (ARTEMIS)
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 18, 2022
A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents with Acute Hepatitis C Virus (HCV) Infection
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 18, 2022
An Observational Study of Patients with Chronic Hepatitis B (CHB) Infection
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 18, 2022
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 22, 2022
A Phase I/Ib Study of BP1002 (a Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML)
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 13, 2022
Ongoing Chronic Hepatitis (HCV) Test and Treat Utilizing Simplified HCV Patient Education
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 30, 2022
A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 2/3 Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients with Symptomatic Polycystic Liver Disease
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 30, 2022